TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00602901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA-SM
Description: High-velocity low amplitude spinal manipulation (HVLA-SM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LVVA-SM
Description: Low-velocity variable amplitude spinal manipulation (LVVA-SM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
Study: NCT01444976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: patients will receive only topical anesthesia with 1% lidocaine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hypnosis
Description: Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hypnosis
Description: Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
Study: NCT04682574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: mega dose is given to the selected critically ill patients
Study: NCT02758678

Intervention type: BIOLOGICAL
Intervention: A single 2 ml heparinised peripheral blood sample
Description: A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:

Intervention type: BIOLOGICAL
Intervention: A single 2 ml heparinised peripheral blood sample
Description: A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:

Intervention type: BIOLOGICAL
Intervention: A single 2 ml heparinised peripheral blood sample
Description: A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
Study: NCT02609555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEM perineal rectopexy
Description: perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
Study: NCT00498537

Intervention type: DRUG
Group type: OTHER
Intervention: spironolactone

Intervention type: DRUG
Group type: OTHER
Intervention: spironolactone
Study: NCT02433327

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEWS - trigger tool
Description: PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RM - trigger tool
Description: RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
Study: NCT04428775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZT-OP1a (cromolyn)
Description: 1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZT-OP1a (cromolyn)
Description: 1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory
Study: NCT02245204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
Study: NCT00222729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV q 21 days following pemetrexed
Study: NCT03525587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of MAGHD App/MAGHD Framework
Description: Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
Study: NCT04205994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 MG
Description: Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
Study: NCT03525587

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of MAGHD App/MAGHD Framework
Description: Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of MAGHD App/MAGHD Framework
Description: Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
Study: NCT01783457

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual psychoeducation
Description: Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request.
Study: NCT01687192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV prophylactic vaccine Gardasil
Description: 3 injections: at Inclusion visit then 2 and 6 months after.
Study: NCT00607516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented primary bipolar hemiarthroplasty of the hip
Description: Cemented primary bipolar hemiarthroplasty of the hip

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented primary bipolar hemiarthroplasty of the hip
Description: Uncemented primary bipolar hemiarthroplasty of the hip
Study: NCT02350361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin 7.5mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02353611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide
Study: NCT01579539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
Study: NCT04205994

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: FMRI provides an indirect and noninvasive measure of brain activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: FMRI provides an indirect and noninvasive measure of brain activity.
Study: NCT01206868

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fenestration
Description: Fenestration of the peritoneum according to the length of the transplanted kidney

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard kidney transplantation
Study: NCT01504568

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment
Description: Adults: ≥40 kg:250mg every eight hours Children: \<40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
Study: NCT02353611

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 35% hydrogen peroxide
Description: conventional peroxide whitening compound acted like control
Study: NCT02467153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RET
Description: RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally as tablets; 1 tablet per day for 6 months.
Study: NCT02467153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
Study: NCT02324335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilacidin
Description: Oral Rinse used 3 times daily for 7 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02179190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BARREL VRD
Description: The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
Study: NCT00288704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rilonacept 160 mg
Description: Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.

Intervention type: DRUG
Group type: OTHER
Intervention: rilonacept 160 mg
Description: Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
Study: NCT02578290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default.
Study: NCT02673008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocyte infusion
Description: DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10\*8 mononuclear cells/kg.
Study: NCT01460992

Intervention type: PROCEDURE
Intervention: Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions
Description: patients will undergo an MRI scan for 30 minutes.
Study: NCT02133274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychosocial Intervention
Description: Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
Study: NCT01759121

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: T-PRP
Description: 532nm-short pulse panretinal photocoagulation with PASCAL function

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: S-PRP
Description: 532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
Study: NCT03386461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega 3 supplementation
Description: Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
Study: NCT03825198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Erector spinae plane block
Description: Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,25%
Description: 20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
Study: NCT03282851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11456
Description: Subjects will receive a single injection of MSB11456 on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Actemra
Description: Subjects will receive a single injection of US-licensed actemra on Day 1.
Study: NCT03825198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spine fusion
Description: fusion of lumbar vertebral body on 1 or two levels
Study: NCT03282851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra
Description: Subjects will receive a single injection of EU-approved RoActemra on Day 1.
Study: NCT01579539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg i.v. infusion once a week for 12 weeks
Study: NCT03825198

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: spine fusion
Description: fusion of lumbar vertebral body on 1 or two levels
Study: NCT00961766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00010 (Neublastin)
Description: Single dose, weight-based IV administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV matched placebo
Study: NCT04226534

Intervention type: OTHER
Group type: OTHER
Intervention: Maximal effort test
Description: Performing a maximal effort test on the treadmill
Study: NCT01519570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
Description: The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
Study: NCT01543373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amphilimus Eluting Stent
Description: Sirolimus formulated coronary eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Description: Bare metal coronary stent
Study: NCT03773211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renaparin
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
Study: NCT02145988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
Study: NCT01601431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap Assisted Colonoscopy
Description: Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional colonoscopy
Description: Regular colonoscopy as per standard clinical guidelines
Study: NCT03480906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Latanoprost ophthalmic solution administered as a microdose spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost ophthalmic solution administered as an eyedrop
Study: NCT00925990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: 5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS-1027
Description: 5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsules identical to ribavirin in appearance containing inactive ingredients
Study: NCT04418284

Intervention type: OTHER
Intervention: survey
Description: online survey
Study: NCT02016430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MeLT Dietary intervention
Description: Mediterranean diet containing food with low TMAO content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC Dietary intervention
Description: Standard American Heart Association (AHA) recommendations for dietary counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MeLT dietary intervention with TMAO
Description: Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
Study: NCT05093478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal capsaicin
Description: Intranasal capsaicin, 5 applications each delivering 2 micrograms in each nostril, separated by 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical lidocaine
Description: The nose will be pre-treated with topical lidocaine 15 minutes before each application
Study: NCT03690453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: single dose of Ivermectin